Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells

Oncogene

Volumn 27, Issue 19, 2008, Pages 2686-2692

  Silva, F Pittella ^a   Hamamoto, R ^a   Kunizaki, M ^a   Tsuge, M ^a   Nakamura, Y ^a   Furukawa, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cancer; Methyltransferase; SMYD3

Indexed keywords

GLYCINE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90ALPHA; HISTONE METHYLTRANSFERASE; PROTEIN SMYD3; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; CELL LINE; CELL LINE, TUMOR; HCT116 CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDES; PROTEIN STRUCTURE, TERTIARY;

EID: 42549095632     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210929     Document Type: Article

References (18)

1. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P et al. (2002). Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298: 1039-4103.
2. Fasulo L, Ugolini G, Visintin M, Bradbury A, Brancolini C, Verzillo V et al. (2000). The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis. J Neurochem 75: 624-633.
3. Fontecave M, Atta M, Mulliez E. (2004). S-adenosylmethionine: nothing goes to waste. Trends Biochem Sci 29: 243-249.
4. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. (2005). Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 1: 143-145.
5. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M et al. (2004). SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6: 731-740.
6. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y et al. (2006). Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 97: 113-118.
7. Jacobs SA, Harp JM, Devarakonda S, Kim Y, Rastinejad F, Khorasanizadeh S. (2002). The active site of the SET domain is constructed on a knot. Nat Struct Biol 9: 833-838.
8. Jenuwein T, Allis CD. (2001). Translating the histone code. Science 293: 1074-1080.
9. Kouzarides T. (2002). Histone methylation in transcriptional control. Curr Opin Genet Dev 12: 198-209.
10. Lachner M, Jenuwein T. (2002). The many faces of histone lysine methylation. Curr Opin Cell Biol 14: 286-298.
11. Marmorstein R. (2003). Structure of SET domain proteins: a new twist on histone methylation. Trends Biochem Sci 28: 59-62.
12. Peterson CL, Laniel MA. (2004). Histones and histone modifications. Curr Biol 14: R546-R551.
13. Rawlings ND, Morton FR, Barrett AJ. (2006). MEROPS: the peptidase database. Nucleic Acids Res 34: D270-D272.
14. Tresaugues L, Dehe PM, Guerois R, Rodriguez-Gil A, Varlet I, Salah P et al. (2006). Structural characterization of Set1 RNA recognition motifs and their role in histone H3 lysine 4 methylation. J Mol Biol 359: 1170-1181.
15. Tsuge M, Hamamoto R, Silva FP, Ohnishi Y, Chayama K, Kamatani N et al. (2005). A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5′ flanking region of SMYD3 is a risk factor for human cancers. Nat Genet 37: 1104-1107.
16. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629.
17. Yang XJ. (2005). Multisite protein modification and intramolecular signaling. Oncogene 24: 1653-1662.
18. Zhang X, Tamaru H, Khan SI, Horton JR, Keefe LJ, Selker EU et al. (2002). Structure of the Neurospora SET domain protein DIM-5, a histone H3 lysine methyltransferase. Cell 111: 117-127.